PASG · XBRL financial data
Passage BIO financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (PASG's year ends in late December)
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.
Balance sheet
CSVFiscal quarters (PASG's year ends in late December)
- ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (September 2025); filings made before it reported them unadjusted.
Cash flows
CSVFiscal quarters (PASG's year ends in late December)
| In thousands of dollars | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (27,110) | (16,758)* | (16,711) | (15,991) | (19,340) | (12,725)* | (15,405) | (9,385) | (7,749) | (12,983)* | (7,559) | (7,821) |
| Stock-based compensation | 2,824* | 1,570* | 1,595 | 1,578* | 1,400* | 1,247* | 858 | 923* | 611* | 609* | 556 | 525* |
| Depreciation and amortization | 1,000 | 807* | 806 | 800 | 800 | 719* | 201 | 200 | 200 | 177* | 129 | 25* |
| Net cash from operating activities | (19,163)* | (19,516)* | (18,929) | (13,136)* | (7,447)* | (8,444)* | (13,847) | (6,330)* | (4,853)* | (6,479)* | (12,987) | (9,181)* |
| Net cash from investing activities | 22,451* | 7,600* | 25,251 | 1,048* | 14,969* | 13,678* | 39,631 | 585* | 0* | 0* | 20 | 0* |
| Net cash from financing activities | 0* | 46* | 8,742 | 85* | 0* | 47* | — | — | 0* | 9* | — | — |
| Net change in cash | 3,288* | (11,870)* | 15,064 | (12,003)* | 7,522* | 5,281* | 25,784 | (5,731)* | (4,853)* | (6,470)* | (12,967) | (9,181)* |
Compare with peers
SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Passage BIO | 24,155 | not reported | (9,181)* | 3.2M | 2.6 quarters | 10-QJun 30, 2026 |
| Pulmatrix | 2,168 | not reported | (1,106)* | 3.7M | 2.0 quarters | 10-QJun 30, 2026 |
| Scynexis | 10,487 | 235 | (14,885)* | 9.9M | 3.6 quarters | 10-QJun 30, 2026 |
| Palatin Technologies | 7,492 | 301* | (2,690)* | 1.8M | 2.8 quarters | 10-KJun 30, 2026 |
| Curis | 5,073 | 0 | (9,646)* | 2.1M | 0.5 quarters | 10-QJun 30, 2026 |
| Kala Bio | 229 | not reported | (1,535)* | 19.3M | 4.7 quarters | 10-QJun 30, 2026 |
| Lexaria Bioscience | 3,500 | 0 | (1,635)* | 24.8M | 2.2 quarters | 10-QMay 31, 2026 |
| Dyadic International | 1,425 | 961 | (1,818)* | 36.4M | 1.7 quarters | 10-QJun 30, 2026 |
| Outlook Therapeutics | 11,242 | not reported | (21,011)* | 243.4M | 0.5 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.